FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3108799736> ?p ?o ?g. }

• W3108799736 endingPage "117" @default.
• W3108799736 startingPage "107" @default.
• W3108799736 abstract "Background BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer. Methods In this phase 3, multicentre, open-label, repeat-dose study done in 33 centres (hospitals and clinics) in the USA, we recruited patients aged 18 years or older, with BCG-unresponsive non-muscle-invasive bladder cancer and an Eastern Cooperative Oncology Group status of 2 or less. Patients were excluded if they had upper urinary tract disease, urothelial carcinoma within the prostatic urethra, lymphovascular invasion, micropapillary disease, or hydronephrosis. Eligible patients received a single intravesical 75 mL dose of nadofaragene firadenovec (3 × 1011 viral particles per mL). Repeat dosing at months 3, 6, and 9 was done in the absence of high-grade recurrence. The primary endpoint was complete response at any time in patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour). The null hypothesis specified a complete response rate of less than 27% in this cohort. Efficacy analyses were done on the per-protocol population, to include only patients strictly meeting the BCG-unresponsive definition. Safety analyses were done in all patients who received at least one dose of treatment. The study is ongoing, with a planned 4-year treatment and monitoring phase. This study is registered with ClinicalTrials.gov, NCT02773849. Findings Between Sept 19, 2016, and May 24, 2019, 198 patients were assessed for eligibility. 41 patients were excluded, and 157 were enrolled and received at least one dose of the study drug. Six patients did not meet the definition of BCG-unresponsive non-muscle-invasive bladder cancer and were therefore excluded from efficacy analyses; the remaining 151 patients were included in the per-protocol efficacy analyses. 55 (53·4%) of 103 patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour) had a complete response within 3 months of the first dose and this response was maintained in 25 (45·5%) of 55 patients at 12 months. Micturition urgency was the most common grade 3–4 study drug-related adverse event (two [1%] of 157 patients, both grade 3), and there were no treatment-related deaths. Interpretation Intravesical nadofaragene firadenovec was efficacious, with a favourable benefit:risk ratio, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. This represents a novel treatment option in a therapeutically challenging disease state. Funding FKD Therapies Oy." @default.
• W3108799736 created "2020-12-07" @default.
• W3108799736 creator A5000811357 @default.
• W3108799736 creator A5001279486 @default.
• W3108799736 creator A5002819180 @default.
• W3108799736 creator A5003263712 @default.
• W3108799736 creator A5003720954 @default.
• W3108799736 creator A5006253852 @default.
• W3108799736 creator A5006702120 @default.
• W3108799736 creator A5007324648 @default.
• W3108799736 creator A5007706410 @default.
• W3108799736 creator A5008376174 @default.
• W3108799736 creator A5013213696 @default.
• W3108799736 creator A5014220812 @default.
• W3108799736 creator A5014340572 @default.
• W3108799736 creator A5014651604 @default.
• W3108799736 creator A5016811631 @default.
• W3108799736 creator A5018670566 @default.
• W3108799736 creator A5018745113 @default.
• W3108799736 creator A5019519297 @default.
• W3108799736 creator A5024685539 @default.
• W3108799736 creator A5025328411 @default.
• W3108799736 creator A5033050573 @default.
• W3108799736 creator A5034005227 @default.
• W3108799736 creator A5041923034 @default.
• W3108799736 creator A5044200134 @default.
• W3108799736 creator A5046653328 @default.
• W3108799736 creator A5047242967 @default.
• W3108799736 creator A5048604566 @default.
• W3108799736 creator A5050166344 @default.
• W3108799736 creator A5050663947 @default.
• W3108799736 creator A5064230008 @default.
• W3108799736 creator A5064387672 @default.
• W3108799736 creator A5067372930 @default.
• W3108799736 creator A5067558680 @default.
• W3108799736 creator A5067816501 @default.
• W3108799736 creator A5068922056 @default.
• W3108799736 creator A5069174478 @default.
• W3108799736 creator A5071741514 @default.
• W3108799736 creator A5077350606 @default.
• W3108799736 creator A5077644150 @default.
• W3108799736 creator A5086081364 @default.
• W3108799736 creator A5087611807 @default.
• W3108799736 creator A5088518998 @default.
• W3108799736 creator A5088970810 @default.
• W3108799736 date "2021-01-01" @default.
• W3108799736 modified "2023-10-17" @default.
• W3108799736 title "Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial" @default.
• W3108799736 cites W1964128918 @default.
• W3108799736 cites W1988328342 @default.
• W3108799736 cites W1993099037 @default.
• W3108799736 cites W2002323018 @default.
• W3108799736 cites W2008782229 @default.
• W3108799736 cites W2029780593 @default.
• W3108799736 cites W2038973683 @default.
• W3108799736 cites W2045188044 @default.
• W3108799736 cites W2045846742 @default.
• W3108799736 cites W2065634378 @default.
• W3108799736 cites W2068108980 @default.
• W3108799736 cites W2091808986 @default.
• W3108799736 cites W2138133517 @default.
• W3108799736 cites W2152106693 @default.
• W3108799736 cites W2152206210 @default.
• W3108799736 cites W2414199713 @default.
• W3108799736 cites W2471695355 @default.
• W3108799736 cites W2599812325 @default.
• W3108799736 cites W2609787832 @default.
• W3108799736 cites W2801888257 @default.
• W3108799736 cites W2895417763 @default.
• W3108799736 cites W2912846485 @default.
• W3108799736 cites W2921560039 @default.
• W3108799736 cites W2956154231 @default.
• W3108799736 cites W2990793439 @default.
• W3108799736 cites W594984707 @default.
• W3108799736 doi "https://doi.org/10.1016/s1470-2045(20)30540-4" @default.
• W3108799736 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7988888" @default.
• W3108799736 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33253641" @default.
• W3108799736 hasPublicationYear "2021" @default.
• W3108799736 type Work @default.
• W3108799736 sameAs 3108799736 @default.
• W3108799736 citedByCount "147" @default.
• W3108799736 countsByYear W31087997362020 @default.
• W3108799736 countsByYear W31087997362021 @default.
• W3108799736 countsByYear W31087997362022 @default.
• W3108799736 countsByYear W31087997362023 @default.
• W3108799736 crossrefType "journal-article" @default.
• W3108799736 hasAuthorship W3108799736A5000811357 @default.
• W3108799736 hasAuthorship W3108799736A5001279486 @default.
• W3108799736 hasAuthorship W3108799736A5002819180 @default.
• W3108799736 hasAuthorship W3108799736A5003263712 @default.
• W3108799736 hasAuthorship W3108799736A5003720954 @default.
• W3108799736 hasAuthorship W3108799736A5006253852 @default.
• W3108799736 hasAuthorship W3108799736A5006702120 @default.
• W3108799736 hasAuthorship W3108799736A5007324648 @default.
• W3108799736 hasAuthorship W3108799736A5007706410 @default.
• W3108799736 hasAuthorship W3108799736A5008376174 @default.
• W3108799736 hasAuthorship W3108799736A5013213696 @default.
• W3108799736 hasAuthorship W3108799736A5014220812 @default.

• next